Hisashi Yamanaka

Hisashi Yamanaka

Auto-generated profile, based on publicly available information

Hisashi Yamanaka

Sanno Medical Center, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
HYHisashi Yamanaka
Hisashi Yamanaka
Gout is a urate deposition disease caused by persistent hyperuricemia. Because gout patients present with a variety of clinical symptoms, it is necessary to have a guideline for the standard management and care of gout and hyperuricemia. The Japanese Society of Gout and Nucleic Acid Metabolism, a scientific society committed to study nucleic acid metabolism and related diseases, established the first edition of the “Guideline for the Management of Hyperuricemia and Gout” in 2002, and published the revised version in January 2010. This second edition is not only evidence based on a search of systemic literature, but also includes consensus levels by a Delphi exercise to determine the strength of the recommendations. A draft version of this guideline was reviewed by internal and external reviewers as well as a patient. In this guideline, key messages from each chapter are listed as statements together with the evidence level, consensus level, and strength of the recommendation. In this proceeding, several selected chapters on the clinical management of gout and hyperuricemia are described. We hope this guideline is appropriately used for the standard management and care of patients with hyperuricemia and gout in daily practice.

8 December 2003 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
YMYuko Matsuda
Yuko Matsuda
GSGurkirpal Singh
Gurkirpal Singh
HYHisashi Yamanaka
Hisashi Yamanaka
ETEiichi Tanaka
Eiichi Tanaka
WUWako Urano
Wako Urano
NKNaoyuki Kamatani
Naoyuki Kamatani
Objective: To develop and validate a self‐administered instrument for measuring functional status in Japanese‐speaking rheumatoid arthritis patients.Methods: We translated the Stanford Health Assessment Questionnaire (HAQ) into Japanese (original HAQ), and then made a tentative Japanese version of the HAQ (J‐HAQ) with culturally appropriate modifications of the arising, eating, and reach category questions. The questionnaire was then administered to 3,763 RA patients (82.6% female; mean age 58.0 years; mean onset age 47.4 years; mean disease duration 10.5 years).Results: This instrument showed excellent internal reliability (Cronbach's α = 0.927), with a mean interitem correlation of 0.60. For the arising category question, the J‐HAQ asks about arising from a futon in addition to a bed because futons are still common in Japanese culture. Arising from a futon is generally more difficult for disabled individuals than is arising from a bed, so the arising score was higher in the J‐HAQ (mean score 0.82) than in the original HAQ (0.48). The average scores for the eating and reach categories were virtually identical for the original HAQ and the J‐HAQ, with correlation coefficients of 0.979 and 0.926, respectively. Thus, the overall disability index (average of the scores for all functional areas) was higher in the J‐HAQ (0.81) than in the original HAQ (0.76), although the correlation coefficient was high (0.993). The test‐retest reliability value (0.92), studied at a 1‐week interval, revealed identical disability index scores measured on the 2 occasions.Conclusion: The final version of the J‐HAQ is a valid and reliable instrument for measuring functional status in Japanese‐speaking RA patients.

22 November 2013 in Modern Rheumatology
Verified
Journal Article
Open access
PDF file
HYHisashi Yamanaka
Hisashi Yamanaka
NSNaonobu Sugiyama
Naonobu Sugiyama
EIEisuke Inoue
Eisuke Inoue
ATAtsuo Taniguchi
Atsuo Taniguchi
SMShigeki Momohara
Shigeki Momohara
Objectives The prevalence of rheumatoid arthritis (RA) and its current treatment practices in Japan are poorly documented. Therefore, we examined these factors in a Japanese health insurance database. Methods We analyzed reimbursement data provided by health insurance societies for 1 million individuals, including healthy individuals, registered from January 2005 to June 2011. Changes in treatments were determined in 320 thousand individuals originally registered in 2005. The treatment patterns were compared with those of the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort managed by Tokyo Women’s Medical University. Results The estimated prevalence of RA was 1.24 million (1.0 % of the Japanese population), excluding suspected cases, and 706 thousand (0.6 %) in a sensitivity analysis. Seventy-nine percent of patients were treated for RA. Methotrexate was used by 27 % of patients. In 2005, 5 % of patients were prescribed methotrexate at >8 mg/week, which increased to 13 % in 2011. These rates were lower than those in the IORRA cohort. Conclusions Our results indicate that the prevalence of RA in Japan is somewhere between 0.6 and 1.0 %. Considering that methotrexate is infrequently used, the implementation of aggressive treatment regimens such as the ‘Treat to Target’ strategy is important to achieve tight control of RA in Japan.

16 March 2022 in Modern Rheumatology
Verified
Journal Article
Open access
PDF file
YKYutaka Kawahito
Yutaka Kawahito
AMAkio Morinobu
Akio Morinobu
YKYuko Kaneko
Yuko Kaneko
MKMasataka Kohno
Masataka Kohno
SHShintaro Hirata
Shintaro Hirata
MHMasayoshi Harigai
Masayoshi Harigai
Objective: The aim of this study was to update the Japan College of Rheumatology (JCR) clinical practice guidelines (CPG) for the management of rheumatoid arthritis (RA; JCR CPG for RA) according to recent changes in the medical environment in Japan. This article is a digest version of the guidance.Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation method to update the 2014 JCR CPG for RA. A consensus was formed by CPG panel members.Results: We identified 36 important clinical questions regarding drug treatment and developed corresponding recommendations for RA. The recommendations included the following RA medications: non-steroidal anti-inflammatory drugs, corticosteroids, conventional synthetic disease-modifying antirheumatic drugs, biological disease-modifying antirheumatic drugs, anti-receptor activator for nuclear factor-κB ligand antibodies, and Janus kinase inhibitors, as well as the tapering and discontinuation of these medications. Recommendations regarding the efficacy and safety of treatments in the elderly and patients with comorbidities were also developed. Finally, we used these recommendations to create an original algorithm for drug treatment for RA based on the Treat-to-Target approach.Conclusion: The 2020 JCR CPG for RA provides a useful tool for rheumatologists, health care professionals, and patients with RA, enabling shared decision-making in a variety of clinical situations.

20 July 2020 in Modern Rheumatology
Verified
Journal Article
Open access
RKRuriko Koto
Ruriko Koto
ANAkihiro Nakajima
Akihiro Nakajima
HHHideki Horiuchi
Hideki Horiuchi
HYHisashi Yamanaka
Hisashi Yamanaka
To assess gout and asymptomatic hyperuricemia in Japan and review treatment conditions. This retrospective cross-sectional study analyzed the prevalence of hyperuricemia and gout, and characteristi...

1 March 2011 in Current Opinion in Rheumatology
Verified
Journal Article
Closed access
HYHisashi Yamanaka
Hisashi Yamanaka
Although gout and hyperuricemia have received considerable attention recently, there is limited information on the two conditions in young people. The molecular mechanisms of hyperuricemia have been investigated extensively in recent years, with this knowledge providing new insights and a better understanding of the precocious onset of gout and hyperuricemia. Serum uric acid levels are higher in the younger generation compared with the older generation. A proportion of gout and hyperuricemia in childhood is due to inborn errors in purine metabolism. Extensive investigation has demonstrated genetic polymorphisms in the urate transporter associated with hyperuricemia and gout. Whether or not polymorphisms affect the onset of gout and hyperuricemia in young people is unclear. Uric acid levels in childhood have also been shown to correlate with the development of the metabolic syndrome. Elevations in serum uric acid levels in childhood are often associated with other diseases and allied conditions. Hyperuricemia in young individuals is often a marker of the metabolic syndrome. Gout is not common in childhood compared with adulthood, and careful consideration of inborn errors of metabolism should be considered in these cases.